TENACITY - A Phase III, Prospective, Randomized, Open-label, Blinded Endpoint Assessment (PROBE) to Assess Efficacy and Safety of i.v. Tenecteplase vs Standard of Care in Patients With Acute Ischemic Stroke (Including Wake-up Stroke), Last Known Well >4.5 h With Imaging Evidence of Salvageable Ischemic Tissue
Latest Information Update: 06 Mar 2026
At a glance
- Drugs Tenecteplase (Primary)
- Indications Ischaemic stroke
- Focus Therapeutic Use
- Sponsors Boehringer Ingelheim
Most Recent Events
- 03 Mar 2026 Status changed from not yet recruiting to recruiting.
- 03 Feb 2026 New trial record